Legal Opinion
Amgen Inc. v. Sanofi, Aventisub LLC
Court of Appeals for the Federal Circuit
Decided October 5, 2017No. 2017-1480PublishedCited by 28 opinions
1Opinion of the Court
PROST, Chief Judge.
Appellants Sanofi, Aventisub LLC, Re-generan Pharmaceuticals Inc., and Sanofi-Aventis U.S., LLC (collectively, “Appellants”) appeal from a final judgment of the district court holding U.S. Patent Nos. 8,829,165 (“’165 patent”) and 8,859,741 (“’741 patent”) not invalid and granting a permanent injunction enjoining sales of Appellants’ Praluent® alirocumab (“Pra-luent”). 1 In particular, Appellants argue that the district court improperly excluded evidence regarding written description and enablement, improperly instructed the jury on written description, improperly denied…
2Cases cited24 opinions
- Ebay Inc. v. Mercexchange, L. L. C.Supreme Court of the United States · 2006
- Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.Court of Appeals for the Federal Circuit · 2010
- Vas-Cath Incorporated and Gambro, Inc. v. Sakharam D. Mahurkar, and Quinton Instruments CompanyCourt of Appeals for the Federal Circuit · 1991
- Brown v. PiperSupreme Court of the United States · 1875
- Genentech, Inc. v. Novo Nordisk, A/s, Novo Nordisk of North America, Inc. And Novo Nordisk Pharmaceuticals, Inc.Court of Appeals for the Federal Circuit · 1997
19 more not listed; retrieve them via the Exa API.
3Cited by28 opinions
- Nuvo Pharm. (Ireland) Designated Activity Co. v. Dr. Reddy's Labs. Inc.Court of Appeals for the Federal Circuit · 2019
- Gilead Sciences, Inc. v. Merck & Co., Inc.Court of Appeals for the Federal Circuit · 2018
- Amgen Inc. v. SanofiCourt of Appeals for the Federal Circuit · 2021
- Amgen Inc. v. SanofiSupreme Court of the United States · 2023
- D Three Enterprises, LLC v. Sunmodo CorporationCourt of Appeals for the Federal Circuit · 2018
23 more not listed; retrieve them via the Exa API.